Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Change in Receivables: 2020-2025

Historic Change in Receivables for Whitehawk Therapeutics (WHWK) over the last 3 years, with Mar 2025 value amounting to $1.0 million.

  • Whitehawk Therapeutics' Change in Receivables rose 280.18% to $1.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.0 million, marking a year-over-year increase of 411.71%. This contributed to the annual value of $415,000 for FY2024, which is 88.55% down from last year.
  • As of Q1 2025, Whitehawk Therapeutics' Change in Receivables stood at $1.0 million, which was up 256.99% from -$637,000 recorded in Q4 2024.
  • Over the past 5 years, Whitehawk Therapeutics' Change in Receivables peaked at $3.7 million during Q1 2023, and registered a low of -$14.0 million during Q1 2021.
  • For the 3-year period, Whitehawk Therapeutics' Change in Receivables averaged around $560,111, with its median value being $620,000 (2024).
  • Per our database at Business Quant, Whitehawk Therapeutics' Change in Receivables plummeted by 437.50% in 2022 and then surged by 930.81% in 2023.
  • Whitehawk Therapeutics' Change in Receivables (Quarterly) stood at -$120,000 in 2021, then slumped by 437.50% to -$399,000 in 2022, then surged by 42.61% to -$229,000 in 2023, then crashed by 178.17% to -$637,000 in 2024, then soared by 280.18% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q1 2025, -$637,000 for Q4 2024, and $620,000 during Q3 2024.